Tag: from-the-late

BioMarin Pharmaceutical Inc’s drug met a study’s main goal of reducing a toxic buildup of an amino acid in the blood of patients with a genetic disorder, but did not show enough benefit in related inattention and mood complications. BioMarin’s shares fell as much as 6 percent in early trading on Monday after the company…